Michael Schlenk MBA
Chief Executive Officer
Michael Schlenk earned a Diplom-Kaufmann degree from University Hamburg, Germany, and an MBA from University Bradford Management Centre, U.K. After 6 years as management consultant in the area of technnology transfer Michael Schlenk worked more than 20 years in the Life Science industry.
During his international career he worked and lived in more than 10 countries. He held positions as strategic consultant, marketing manager, area manager, general manager and president of subsidaries of Novartis and Abbott. Before joining Centogene Michael was CEO of Berlin based Biotechnology company ProBioGen AG for 7 years. He led the company to sustained profitability and prepared it for the trade sale. The organisation under his leadership achieved numerous awards for fast growth and technological excellence: Deloitte Fast Forward Award (2 times), Step Award (FAZ German news paper), BMBF and Peta. In 2010 ProBioGen AG was sold successfully to a leading Egyptian Pharma company.
Since 2003 Michael develops and invests as busines angel in young IT and Life Science companies. He is a member of various supervisory boards.
In January 2011 Michael Schlenk invested, became shareholder and was named Chief Executive Officer (CEO) of the Centogene AG. Systematic marketing through international partnerships and collaborations and a professional development of the organisation shall prepare for aggressive expansion of Centogene worldwide. Michael strongly believes in sustained success through high level of empowerment, open communications and teamwork.
Christoph Ehlers LLM
Managing Director and General Counsel
Christoph Ehlers is a fully qualified lawyer who obtained his degrees from the University of Konstanz, Germany, and the University of San Diego, CA. From 1983 to 1997, he held different positions at Commerzbank AG, Germany’s second largest private bank, e.g. in investment banking and as executive assistant to the CEO. From 1992 to 1997, he was responsible for the management of all branches in Southwestern Germany.
Since 1997, he has also been working as a business angel concentrating on developing technology driven companies, especially in Life Science. Under his leadership numerous German companies thrived to success. Apart from his involvement in the technological sector, Christoph Ehlers is a managing partner of Equicore Beteiligungs GmbH, a fellow partner of Freiburger Vermögensmanagement GmbH (a German asset management company) and chairman of the foundation of ordoliberalism of the Center for European Policy, all based in Freiburg. In addition he is a member of various consulting boards.
Christoph has been shareholder and member of the board of directors of Centogene AG, formerly Arcensus AG, and managing director of Centogene AG in Rostock since 2008.
Stefan Maeser PhD
Chief Marketing Officer
Stefan Maeser studied biochemistry at the Free University of Berlin, worked at the Max-Planck-Institute for Molecular Genetics in Berlin and the Institute for Genebiological Research Berlin GmbH and continued as a NATO research fellow at the Institute for Molecular Virology, University of Wisconsin – Madison, USA.
He joined Life Technologies Inc. in Germany and worked as marketing manager. Stefan Maeser worked with Genzyme in Germany and Switzerland and became sales and marketing manager and a member of the German management team. He continued his career as CEO of the start-up companies Arcensus AG and GeneBanking AG. After the collapse of the new market Stefan Maeser joined Genzyme´s European headquarters in the Netherlands as business unit head, responsible for Europe and the Middle East. He became a member of the German management team of Genzyme and worked as business unit head in Germany, Austria and Switzerland. The last five years at Genzyme Stefan Maeser worked in Central and East Europe on the scale up of Genzyme´s sales and marketing and medical affairs infrastructure, on financial planning, integration of new products, business development and was a member of the central European management team.
Since July 2011 Stefan Maeser works as Chief Marketing Officer for Centogene AG. He is also a shareholder of the AG.
Christine Uekert BA
Chief Financial Officer
In July 2011 Christine Uekert joined Centogene AG as Director Finance and Administration.
Prior to joining Centogene Christine held various senior management positions in finance, controlling and administration in IT businesses like SPM Technologies and SAP.
2006 she joined the Life Science industry and worked as Director of Finance & Administration at ProBioGen AG, a CDMO and technology provider with focus on cell line engineering. Later she took over an administrative position at OD-OS GmbH, a venture-capitalized medical device company in the area of ophthalmology.
During her career she was focused especially on emerging growth and turn around processes including restructuring projects, implementation of state-of-the-art finance systems and complex M&A and financing projects.
Shivendra Kishore PhD
Shivendra brings to Centogene a multi-faceted background, which combines biochemical engineering, academic research and strategy healthcare consulting carried out in diverse cultural environments.
He holds a Bachelor and Master degree in Biochemical Engineering and Biotechnology from Indian Institute of Technology, Delhi, India. He subsequently forayed into natural sciences at Friedrich Alexander University of Erlangen-Nürnberg, Germany where he earned his PhD in Biochemistry, specializing in splicing-related diseases and non-coding RNA involved in genetic abnormalities, in particular Prader Willi Syndrome. Post PhD, Shivendra worked in US and Switzerland where he made further inroads into dissecting the molecular mechanism behind Parder Willi Syndrome. As an European Molecular Biology Laboratory long term-fellow, he further specialized in RNA- and DNA-Biology, in specific, small RNAs and RNA binding proteins using emerging high throughput techniques. He identified the role of EWSR1 protein in stabilizing the recombination hot-spots that are prone to rearrangements in various cancers. Over the years, he has led several independent projects and secured independent funding from both government and private foundations.
Prior to joining Centogene, he worked briefly as an associate consultant with Stratas Partners, a global strategic healthcare consultancy, with a strong focus on strategic market access and pricing.
At Centogene, Shivendra continues to assess and implement emerging technologies towards diagnosing rare diseases.